Drug Trial Radar · NCT05856331
Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema
Last checked: Nov 19, 2026Latest source record: Aug 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
99
Actual
Start
Oct 12, 2023
Primary completion
Aug 6, 2025
Study completion Aug 6, 2025
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- May 12, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 2 study to compare SAR447537 (INBRX-101) to plasma derived A1PI therapy in adults with AATD emphysema
Conditions
- Alpha 1-Antitrypsin Deficiency
- Emphysema
Interventions
SAR447537Drug
A1PI, Recombinant, Bivalent Fc Fusion Protein
ZemairaDrug
Alpha1-Proteinase Inhibitor (Human)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Serum functional AAT (fAAT) levels at steady-stateTime frame: 32 Weeks
Locations
65 sites in 8 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham- Site Number : 105
Birmingham, Alabama
University of Alabama at Birmingham
Birmingham, Alabama
St Joseph's Hospital and Medical Center- Site Number : 126
Phoenix, Arizona
St Joseph's Hospital and Medical Center
Phoenix, Arizona
David Geffen School of Medicine- Site Number : 124
Los Angeles, California
David Geffen School of Medicine
Los Angeles, California
UC Davis Comprehensive Cancer Center- Site Number : 110
Sacramento, California
UC Davis Medical Center
Sacramento, California
National Jewish Medical and Research Center- Site Number : 123
Denver, Colorado
National Jewish Medical and Research Center
Denver, Colorado
Western Connecticut Medical Group
Danbury, Connecticut
University of Florida College of Medicine- Site Number : 101
Gainesville, Florida
University of Florida
Gainesville, Florida
Bruce W. Carter Miami VA Medical Center - NAVREF - PPDS- Site Number : 114
Miami, Florida
University of Miami
Miami, Florida
Pulmonary and Sleep of Tampa Bay- Site Number : 115
Tampa, Florida
Pulmonary and Sleep of Tampa Bay
Tampa, Florida
Loyola University Medical Center- Site Number : 112
Maywood, Illinois
Loyola University Medical Center
Maywood, Illinois
Indiana University
Indianapolis, Indiana
M Health Fairview Clinics and Surgery Center - Minneapolis- Site Number : 125
Minneapolis, Minnesota
M Health Fairview Clinics and Surgery Center - Minneapolis
Minneapolis, Minnesota
Hannibal Regional Healthcare System-HRMG-Hannibal- Site Number : 111
Hannibal, Missouri
Hannibal Clinic
Hannibal, Missouri
Columbia University Irving Medical Center- Site Number : 104
New York, New York
Oregon Health and Science University- Site Number : 117
Portland, Oregon
Oregon Health and Science University
Portland, Oregon
Clinical Research Associates Of Central PA , LLC- Site Number : 128
DuBois, Pennsylvania
Clinical Research Associates Of Central PA , LLC
DuBois, Pennsylvania
Penn State Health Milton S. Hershey Medical Center- Site Number : 122
Hershey, Pennsylvania
Penn State Health Milton S. Hershey Medical Center
Hershey, Pennsylvania
Temple University Hospital- Site Number : 130
Philadelphia, Pennsylvania
Temple University Hospital
Philadelphia, Pennsylvania
Velocity Clinical Research - Spartanburg - PPDS- Site Number : 120
Spartanburg, South Carolina
Velocity Clinical Research - Spartanburg - PPDS
Spartanburg, South Carolina
Houston Methodist Hospital- Site Number : 113
Houston, Texas
Houston Methodist Hospital
Houston, Texas
University of Utah Health
Salt Lake City, Utah
University of Utah Health Care- Site Number : 106
Salt Lake City, Utah
Investigational Site Number : 201
Adelaide, Australia
Showing 40 of 65 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.